Molbio Diagnostics IPO Opens: GMP at 16% Premium
Scientist operating a molecular diagnostic platform in an Indian R&D facility.
Key Highlights
Molbio Diagnostics IPO launched August 10, 2026, at ₹940 crore value and a 16% grey market premium. Explore details and subscription recommendations.
Molbio Diagnostics’ initial public offering () opened for bidding on August 10, 2026. The offer, valued at approximately ₹940 crore, suggests a 16 percent premium over its upper price band. It closes on August 12.
IPO at a Glance
- Total IPO Value: approximately ₹940 crore
- : ₹200 crore
- (OFS): ₹739.70 crore
- : ₹768 to ₹807 per share
- (GMP): ₹132
- Estimated Listing Price: ₹939
- Premium over upper price band: 16 percent
Molbio Diagnostics specializes in point-of-care molecular diagnostic platforms. They focus on rapid and cost-effective solutions for various diseases.
Proceeds from the fresh issue will fund capital expenditure for R&D facilities, a Centre of Excellence, and plant and machinery in Goa and Visakhapatnam. General corporate purposes are also included.
Brokerages Weigh In
Brokerages have largely recommended subscribing to the IPO for long-term investment. They cite the company’s strong market position and financial health.
- Swastika noted a favorable long-term outlook, healthy return ratios, and margin expansion. Valuations align with industry averages.
- SBI Securities highlighted robust financial performance from FY24-26, with significant growth in revenue, , and adjusted . They consider the issue reasonably valued.
- Master Capital identified Molbio Diagnostics as a strong long-term opportunity. They pointed to its proprietary Truenat platform, competitive position, and global patent portfolio.
Molbio Diagnostics shares are slated for listing on both the and . This is expected on August 17.